The molecular classifier was based on OS predictions and segregate AML into 3 groups (Supplemental Table S4, Supplemental Digital Content and Fig. 6A): favorable molecular risk (RUNX1–RUNX1T1 or CBFB–MYH11 or NPM1 mutation or CEBPAdm, n = 142); poor molecular risk (NUP98 fusion or RUNX1 or WT1 or PHF6 mutation, n = 59); intermediate molecular risk (all others, n = 184). Here, PHF6 is linked to acute myeloid leukemia.